The fact that atrazine uses the aromatase pathway to increase estrogen production is important, because it means the chemical could work directly
against aromatase inhibitors, a class of drugs used to treat breast cancer.
Not exact matches
Enzalutamide is also being evaluated in a phase 2 clinical trial in combination with the
aromatase inhibitor exemestane (NCT02007512) and demonstrated promising results in another phase 2 trial
against estrogen - receptor - negative advanced disease (NCT01889238).